Tim Cooke | CEO
Omniose

Tim Cooke, CEO, Omniose

 Dr. Cooke has over thirty years of experience in the biopharmaceutical industry with a focus on vaccines.  He was previously CEO of NovaDigm Therapeutics, CEO of Mojave Therapeutics, COO at AVANT Immunotherapeutics, and SVP at Ology Bioservices. Prior to his leadership roles in the biotechnology industry, he held several positions at Merck establishing a global vaccine-focused marketing and sales organization. Dr. Cooke was the Biotechnology Industry Representative to the U.S. National Vaccine Advisory Committee during 2015-2023. He currently serves on the Klebsiella pneumoniae Working Group of the World Health Organization Collaborative Open Research Consortium on priority bacterial pathogens.  He was previously on the Advisory Board of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and was an observer on the WHO Technical Advisory Group on Vaccines and Antimicrobial Resistance.  He was also Co-Chair of the BIO Vaccine Policy Advisory Committee and was on the Incentives for Vaccines Working Group of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Dr. Cooke was the Vaccine Industry Representative to the Working Group of Gavi, the Vaccine Alliance during its formation in 2000. Dr. Cooke has a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University and a B.S. from Saint Joseph’s University.

Appearances:



Day 2 (21st October) @ 15:00

Updates on Klebsiella vaccines

last published: 21/May/26 10:15 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2026

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com


Stan Dooley

Stan.Dooley@terrapinn.com

 

TO SPEAK


Isla Sutherland

Isla.Sutherland@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.